Thus, the blockade of EGFR by inhibitors like Gefitinib significantly inhibits the tumor cell proliferation; while despite the promising clinical efficacy of these inhibitors, most responders eventually obtained resistance. This evidence concerns the gene EGFR and neoplasm.